Modeling the catarrhal stage of Bordetella pertussis upper respiratory tract infections in mice.
Bordetella pertussis
Catarrhal stage
Mouse
Shedding
TLR4 receptor
Journal
Disease models & mechanisms
ISSN: 1754-8411
Titre abrégé: Dis Model Mech
Pays: England
ID NLM: 101483332
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
received:
01
09
2021
accepted:
14
03
2022
pubmed:
22
3
2022
medline:
6
5
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
Pertussis (whooping cough) is a highly transmissible human respiratory disease caused by Bordetella pertussis, a human-restricted pathogen. Animal models generally involve pneumonic infections induced by depositing large numbers of bacteria in the lungs of mice. These models have informed us about the molecular pathogenesis of pertussis and guided development of vaccines that successfully protect against severe disease. However, they bypass the catarrhal stage of the disease, when bacteria first colonize and initially grow in the upper respiratory tract. This is a critical and highly transmissible stage of the infection that current vaccines do not prevent. Here, we demonstrate a model system in which B. pertussis robustly and persistently infects the nasopharynx of TLR4-deficient mice, inducing localized inflammation, neutrophil recruitment and mucus production as well as persistent shedding and occasional transmission to cage mates. This novel experimental system will allow the study of the contributions of bacterial factors to colonization of and shedding from the nasopharynx, as occurs during the catarrhal stage of pertussis, and interventions that might better control the ongoing circulation of pertussis.
Identifiants
pubmed: 35311902
pii: 274790
doi: 10.1242/dmm.049266
pmc: PMC9092653
pii:
doi:
Substances chimiques
Pertussis Vaccine
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R21 AI116186
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI156293
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI149787
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI159347
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI140399
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI142678
Pays : United States
Informations de copyright
© 2022. Published by The Company of Biologists Ltd.
Déclaration de conflit d'intérêts
Competing interests The authors declare no competing or financial interests.
Références
Infect Immun. 2003 Apr;71(4):1719-24
pubmed: 12654784
Clin Infect Dis. 2013 May;56(9):1248-54
pubmed: 23487373
Elife. 2021 Jun 07;10:
pubmed: 34097599
Immunobiology. 2016 Mar;221(3):399-411
pubmed: 26686909
Infect Immun. 2010 May;78(5):2060-9
pubmed: 20176798
PLoS One. 2014 Jan 30;9(1):e85229
pubmed: 24497924
PLoS Pathog. 2013;9(7):e1003418
pubmed: 23935481
Annu Rev Physiol. 2011;73:479-501
pubmed: 21054166
PLoS Pathog. 2022 Apr 8;18(4):e1010402
pubmed: 35395059
Mucosal Immunol. 2018 Nov;11(6):1763-1776
pubmed: 30127384
Vaccines (Basel). 2020 Nov 19;8(4):
pubmed: 33228165
PLoS Pathog. 2005 Dec;1(4):e45
pubmed: 16389302
Clin Microbiol Rev. 2016 Jul;29(3):449-86
pubmed: 27029594
NPJ Vaccines. 2021 Jan 8;6(1):6
pubmed: 33420041
Front Endocrinol (Lausanne). 2013 Sep 18;4:129
pubmed: 24065956
J Biol Chem. 2007 Aug 10;282(32):23603-12
pubmed: 17580308
Nat Immunol. 2002 Apr;3(4):354-9
pubmed: 11912497
Am J Public Health Nations Health. 1934 Apr;24(4):309-18
pubmed: 18013967
Immunol Rev. 2016 Nov;274(1):33-58
pubmed: 27782325
J Biol Chem. 2015 May 22;290(21):13440-53
pubmed: 25837248
J Gen Microbiol. 1970 Oct;63(2):211-20
pubmed: 4324651
J Egypt Public Health Assoc. 2019;94(1):5
pubmed: 30713347
Infect Immun. 2005 Dec;73(12):8144-52
pubmed: 16299309
Infect Immun. 2021 Feb 16;89(3):
pubmed: 33318136
Clin Infect Dis. 2020 Jan 1;70(1):152-161
pubmed: 31257450
Immunol Rev. 2001 Apr;180:35-48
pubmed: 11414361
J Infect Dis. 2014 Mar;209(6):913-21
pubmed: 24227794
Infect Immun. 1999 Nov;67(11):6109-18
pubmed: 10531274
Front Immunol. 2014 Sep 25;5:461
pubmed: 25309543
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):E944-53
pubmed: 22451944
CMAJ. 2003 Feb 18;168(4):453-4
pubmed: 12591789
J Immunol. 2003 Sep 15;171(6):3119-27
pubmed: 12960338
Front Immunol. 2014 Jul 10;5:316
pubmed: 25071777
BMC Genomics. 2016 Sep 30;17(1):767
pubmed: 27716057
J Immunol. 2010 Apr 1;184(7):3889-96
pubmed: 20194726
Emerg Infect Dis. 2021 Aug;27(8):2107-2116
pubmed: 34286682
Infect Immun. 2017 Oct 18;85(11):
pubmed: 28784932
Nat Genet. 2003 Sep;35(1):32-40
pubmed: 12910271
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):787-92
pubmed: 24277828
PLoS One. 2009;4(1):e4280
pubmed: 19169359
Expert Rev Vaccines. 2012 Sep;11(9):1121-37
pubmed: 23151168
BMC Evol Biol. 2013 Sep 25;13:209
pubmed: 24067113
Nat Rev Microbiol. 2014 Apr;12(4):274-88
pubmed: 24608338
CMAJ. 2005 Feb 15;172(4):509-15
pubmed: 15710944
Clin Infect Dis. 2008 Aug 1;47(3):328-38
pubmed: 18558873